The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

When examining Regeneron Pharmaceuticals in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent: Regeneron Pharmaceuticals is in a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Regeneron (REGN) closed the most recent trading day at $595.73, moving +1.54% from the previous trading session. This change lagged the S&P 500's 2.76% gain on the day. Meanwhile, the Dow gained 2 ...

In this article, we will perform a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:REGN) against its key competitors in the Biotechnology industry. By analyzing ...

The study featured a head-to-head comparison between Pfizer's drug and Dupixent, which is marketed by Sanofi (SNY 0.12%) and Regeneron (REGN-3.69%). Could Pfizer beat Sanofi and Regeneron in the ...

Current Position of Regeneron Pharmaceuticals Currently trading with a volume of 389,940, the REGN's price is down by -1.07%, now at $1034.78. RSI readings suggest the stock is currently may be ...